Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “sector perform” rating restated by equities researchers at RBC Capital Markets in a research note issued on Tuesday.

VRX has been the subject of a number of other research reports. Mizuho reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, May 31st. Morgan Stanley reiterated a “positive” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, August 19th. Rodman & Renshaw reiterated a “buy” rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 28th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research note on Monday, June 27th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $28.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Six investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $56.09.

Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.196% on Tuesday, reaching $26.505. The company’s stock had a trading volume of 9,114,700 shares. Valeant Pharmaceuticals International has a 52 week low of $18.55 and a 52 week high of $225.54. The company’s market capitalization is $9.21 billion. The firm’s 50 day moving average price is $27.50 and its 200-day moving average price is $29.38.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/valeant-pharmaceuticals-international-inc-vrx-earns-sector-perform-rating-from-rbc-capital-markets-2.html

Valeant Pharmaceuticals International (NYSE:VRX) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.47 billion. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The business’s revenue was down 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.14 earnings per share. On average, equities analysts predict that Valeant Pharmaceuticals International will post $6.54 EPS for the current year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas bought 4,000 shares of the stock in a transaction that occurred on Thursday, August 11th. The shares were purchased at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the transaction, the director now directly owns 20,726 shares in the company, valued at $510,895.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.37% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc boosted its position in shares of Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock valued at $31,830,000 after buying an additional 33,247 shares during the period. Okumus Fund Management Ltd. boosted its position in shares of Valeant Pharmaceuticals International by 98.5% in the first quarter. Okumus Fund Management Ltd. now owns 3,722,464 shares of the specialty pharmaceutical company’s stock valued at $97,901,000 after buying an additional 1,846,864 shares during the period. LPL Financial LLC boosted its position in shares of Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock valued at $2,616,000 after buying an additional 36,046 shares during the period. Seven Eight Capital LLC purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $374,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $1,728,000. Hedge funds and other institutional investors own 63.60% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.